Soo-Ryum Yang, MD

Articles

Insights on the LANCE Pilot Study on Lung LCNEC

December 23rd 2024

Panelists discuss their impressions of the LANCE pilot study for atezolizumab in lung large cell neuroendocrine carcinoma (LCNEC) and its potential impact on treatment strategies.

The Role of DLL3 in LCNEC of the Lung

December 23rd 2024

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

Lung LCNEC Disease Histology and Prognosis

December 16th 2024

Panelists discuss the typical treatment approach for patients with lung large cell neuroendocrine carcinoma (LCNEC), the patient-specific factors considered in first-line treatment selection, insights from the ASCO 2024 retrospective studies on first-line systemic treatment outcomes, and key considerations for choosing a second-line treatment strategy.

A Multidisciplinary Approach to Managing Lung LCNEC

December 16th 2024

Panelists discuss the vital multidisciplinary coordination needed to optimize care for patients with lung large cell neuroendocrine carcinoma (LCNEC), including the roles of various specialists, ensuring alignment on diagnosis, risk assessment, and treatment goals, and the importance of involving the patient in these discussions.

Lung LCNEC Diagnostic Challenges

December 9th 2024

Panelists discuss the challenges encountered with molecular or pathology testing for lung large cell neuroendocrine carcinoma (LCNEC) and how treatment plans are determined when testing is not feasible.

Biopsy Best Practices: Diagnosing Lung LCNEC

December 9th 2024

Panelists discuss the factors that influence the decision to perform a fine needle aspirate vs an incisional biopsy, whether testing is conducted in-house or at a central laboratory, and how the results of these tests impact the treatment plan for patients with lung large cell neuroendocrine carcinoma (LCNEC).

Biomarker Testing Strategies for Lung LCNEC

December 2nd 2024

Panelists discuss how biomarker testing for lung large cell neuroendocrine carcinoma (LCNEC) is approached, covering the frequency and types of tests used, such as NGS, the timing of DLL3 testing, and the factors influencing the choice between fine needle aspirate and other biopsy techniques.

The Pathological Diagnosis of Lung LCNEC

December 2nd 2024

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is diagnosed, including the challenges associated with its differential diagnosis.

An Overview of the Molecular Characterization of Lung LCNEC

November 25th 2024

Panelists discuss how the characterization and classification of lung large cell neuroendocrine carcinoma (LCNEC) has evolved over the past decade, highlighting the clinical heterogeneity of these tumors and how it is navigated in clinical practice.

Lung Large Cell Neuroendocrine Carcinoma: A Rare but Aggressive Disease Intro

November 25th 2024

Panelists discuss how lung large cell neuroendocrine carcinoma (LCNEC) is characterized by its biology, incidence, risk factors, clinical presentation, and prognosis, while addressing the challenges, unmet needs, and the trial data required to guide testing and treatment guidelines for this rare cancer.